Designing liposomal anticancer drug formulations for specific therapeutic applications

Journal of Liposome Research

Volumn 10, Issue 2-3, 2000, Pages 99-115

  Mayer, L D ^a   Krishna, R ^a   Webb, M ^a   Bally, M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cancer therapy; Doxorubicin; Liposomal drug delivery; Vincristine

Indexed keywords

GLYCOPROTEIN; LIPOSOME; MACROGOL; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; LIGAND BINDING; LIPID COMPOSITION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TEMPERATURE;

EID: 0033784548     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.3109/08982100009029381     Document Type: Review

References (31)

1. Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin
2. Liposome pharmacokinetics
3. Long-circulating (sterically stabilized) liposomes for targeted drug delivery
4. Sterically stabilized liposomes
5. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice
6. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro
7. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size
8. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue
9. Sphingomyelincholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumor models
10. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis Lung carcinoma: The lack of beneficial effects by coating liposomes with poly(ethylene glycol)
11. The Liposome Company: Lipid-based pharmaceuticals in clinical development
12. Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin): Sequus Pharmaceuticals, Inc.
13. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts
14. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor acitivity
15. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice
16. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice
17. Anti-HER2 immunoliposomes for targeted therapy of human tumors
18. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma
19. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation
20. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat
21. Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in liposomes
22. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial?
23. MDR expression in normal tissues: Pharmacologic implications for the clinical use of P-glycoprotein inhibitors
24. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukemia
25. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug resistant solid tumors
26. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administring Valspodar (PSC 833) with sterically stabilized liposomal doxorubicin
27. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of Valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion
28. Liposomal vincristine preparations which exhibit decreased toxicity and increased anti-tumour activity against murine L1210 and P388 tumours
29. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumors
30. Optimization of vincristine retention in liposomes in vitro and in vivo
31. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors